DLGAP2 and Alzheimer disease: At 6 months, DLGAP2 overexpression decreased potentiation compared to controls in 5XFAD animals; however, by 14 months, neither controls nor DLGAP2 overexpressing mice exhibited LTP, regardless of AD status (Figure 3B), possibly because a floor effect prevents measuring diminished LTP past this point.